Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. (Q40300097)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

M H Bridgland-Taylor

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

A C Hargreaves

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

A Easter

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

A Orme

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

D C Henthorn

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

M Ding

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

A M Davis

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

C G Heapy

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

N Abi-Gerges

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

F Persson

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

I Jacobson

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

M Sullivan

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

N Albertson

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

T G Hammond

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

E Sullivan

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

J-P Valentin

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

C E Pollard

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

6 March 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

Journal of Pharmacological and Toxicological Methods

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

189-199

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16563806%20AND%20SRC:MED&resulttype=core&format=json

A radiolabeled peptide ligand of the hERG channel, [125I]-BeKm-1.

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Predictive in silico modeling for hERG channel blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

A model for identifying HERG K+ channel blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

The binding of drugs to hepatocytes and its relationship to physicochemical properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

In silico approaches to predicting drug metabolism, toxicology and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

[3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Open channel block of HERG K(+) channels by vesnarinone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Understanding the Structure−Activity Relationship of the Human Ether-a-go-go-Related Gene Cardiac K+ Channel. A Model for Bad Behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Modulation of HERG potassium channels by extracellular magnesium and quinidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Rb+ flux through hERG channels affects the potency of channel blocking drugs: correlation with data obtained using a high-throughput Rb+ efflux assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

A virtual screening method for prediction of the HERG potassium channel liability of compound libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Ionworks HT: a new high-throughput electrophysiology measurement platform.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Drugs, QT interval prolongation and ICH E14: the need to get it right

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Functional and pharmacological properties of canine ERG potassium channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Mechanism of block and identification of the verapamil binding domain to HERG potassium channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003

Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.003